He tried an experimental payload that contained two ADCs, one BRAF inhibitor and something else, maybe PD-1 inhibitor. Then he had surgery. Payload-heavy ADCs are the way forward against difficult cancers.
They're using weakened viruses. Virus use in cancer is nothing new, but an interesting field. I can see why pharma hesitates using it, viruses can mutate, too, similar to cancer.
https://pakrozee.pk/
